Hutchmed (HCM) said Monday it has initiated the withdrawal and recall of Tazverik in mainland China, Hong Kong and Macau after Ipsen decided to voluntarily withdraw the drug from the US market.

The company said Ipsen infomred it that the decision followed a review of emerging data from the phase 1b/3 trial in follicular lymphoma.

An independent data monitoring committee concluded that risks may outweigh benefits for patients in the treatment regimen, the company said, citing Ipsen.

Hutchmed said it has suspended sales and shipments of the drug, notified healthcare institutions to stop prescribing it and pharmacies to cease dispensing it, and is discontinuing all active tazemetostat clinical trials in China.

Hutchmed said the withdrawal is not expected to affect its financial guidance, noting that sales of Tazverik totaled about $2.5 million in 2025.